Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease

This educational symposium provided an insight into the most current clinical evidence of the efficacy and safety of renin—angiotensin—aldosterone system inhibitors (RAASis) for patients with chronic kidney disease (CKD). The programme provided an opportunity to discuss ways to optimise and maintain RAASis in this population by introducing CKD patient cases and the dilemmas of their clinical presentation, and novel treatment options, including benefits, harms, and potential consequences. Prof David C. Wheeler introduced the debate about the use of RAASis and the associated risk of hyperkalaemia in CKD patients. Prof Francesco Locatelli discussed the management of blood pressure (BP) in CKD and reviewed the most current guidelines for the prevention of hyperkalaemia in this population. Prof Adrian Covic presented the controversies around the use of RAASis in specific group populations. Survival, cardiovascular events (CVEs), and progression of CKD were the main points of his presentation. Finally, Prof David C. Wheeler discussed the latest research on novel therapies for the management of hyperkalaemia.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease

Cited by 2 publications

References 20 publications

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease

The Ongoing Management of Hyperkalaemia in Chronic Kidney Disease Patients: Cases for Clinical Decisions

Contact Info

Product

Resources

About